Neurocrine Biosciences Earnings Call Highlights Growth Momentum
Neurocrine Biosciences ((NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurocrine Biosciences struck an upbeat tone on its latest earnings call, underscoring strong commercial execution and a clear path for continued growth. Management highlighted 22% year-over-year revenue expansion, a standout first full year for CRENESSITY, and growing clinical momentum, while framing pricing pressure and higher spending as manageable trade-offs for long-term value creation.
Record Revenue Underscores Growth Profile
Neurocrine reported more than $2.8 billion in total product sales for 2025, a 22% increase versus 2024 that set a new company record. Management emphasized that this growth was driven primarily by higher volumes rather than price, reinforcing the underlying demand for its neurology and endocrine franchises.
INGREZZA Remains a Durable Growth Engine
Flagship drug INGREZZA delivered just over $2.5 billion in 2025 revenue, up 9% year over year despite pricing headwinds. The company expects INGREZZA sales to climb to $2.7–$2.8 billion in 2026, supported by double-digit volume growth, an enlarged sales force and broadly stable net pricing relative to late 2025 levels.
CRENESSITY’s Launch Delivers a Strong First Year
CRENESSITY generated more than $300 million in net sales in its first full commercial year and has already reached about 10% of the classic CAH population. Management pointed to rapid reimbursement decisions, favorable refill behavior and more than 550 patient-years of real-world exposure as signs of a durable launch trajectory.
Clinical Profile Strengthens CRENESSITY Differentiation
The company highlighted open-label data showing durable ACTH and androgen reductions over two years, with about 80% of CRENESSITY patients remaining on therapy at that mark. Additional findings, including meaningful improvements in steroid dosing, weight and predicted adult height in children, underpin its claims of both efficacy and safety in CAH.
INGREZZA Shows Receptor-Occupancy Edge
Neurocrine drew attention to head-to-head PET imaging that showed INGREZZA achieved nearly twice the VMAT2 receptor occupancy versus AUSTEDO XR at therapeutic doses. Management argued this occupancy advantage supports differentiated efficacy and could help defend share as competition intensifies in movement disorders.
Robust Cash Generation and Margin Profile
The company exited 2025 with about $2.5 billion in cash and investments, up roughly $700 million from the prior year, reflecting strong cash generation. Non-GAAP operating margin of around 30% translated to about $850 million in non-GAAP operating income, giving Neurocrine ample flexibility to fund late-stage trials and commercial expansion.
Pipeline Productivity Fuels Long-Term Optionality
Executives described 2025 as the company’s most productive clinical year, meeting objectives across Phase I to III. Key assets include NBI-’890 entering Phase II as a potential VMAT2 follow-on, advancement of NBI-’675, and two Phase III neuropsychiatry programs in depression and schizophrenia with pivotal data expected in 2027.
Stepped-Up Commercial Investment to Extend Reach
Neurocrine is scaling its commercial footprint, with larger sales teams planned for both INGREZZA and CRENESSITY and new CRENESSITY field staff rolling out in April 2026. The company is also investing in AI-based patient-finding tools and broader medical education to deepen penetration among both endocrinology and non-endocrinology prescribers.
Pricing and Formulary Trade-Offs Weigh on Net Price
Management acknowledged that enhanced formulary access has come at the cost of greater pricing concessions, translating to an estimated 4% pricing drag year over year. While volume gains have more than offset these pressures so far, investors were reminded that contracting decisions made in 2025 will continue to influence net pricing dynamics.
CRENESSITY Still Early in Prescriber Penetration
Despite a strong first year, CRENESSITY’s launch is still in its early innings, with quarter-to-quarter start forms showing variability and no 2026 revenue guidance offered. More than 1,000 physicians have written at least one prescription, yet about two-thirds have treated only a single patient, highlighting substantial room to deepen adoption.
Higher SG&A and R&D to Support the Next Leg
Operating expenses are rising as Neurocrine funds a broader field force and several late-stage trials, with GAAP SG&A expected in the low-40% of sales and GAAP R&D in the mid-30% range for 2026. Management framed this step-up as a temporary investment phase, with major Phase III spending expected to taper after 2027.
Competitive and Access Risks on the Horizon
The company flagged medium-term uncertainty from both competitive pipelines and future formulary decisions, including changes expected around 2027. Potential new entrants in CAH and evolving reimbursement frameworks for VMAT2 agents could pressure access and pricing, even as management expressed confidence in its differentiated data.
Launch Seasonality and Gross-to-Net Still Unclear
For CRENESSITY, management said it is too early to define normal seasonality patterns or steady-state patient additions, complicating near-term modeling. A roughly 5% first-quarter gross-to-net impact from a commercial co-pay reset may also distort Q1 comparisons, particularly for analysts focused on short-term trends.
Guidance Signals Growth with Elevated Investment
For 2026, Neurocrine guided INGREZZA revenue to $2.7–$2.8 billion, implying about 10% growth driven mainly by higher volumes with a built-in 4% pricing headwind. At the company level, management expects continued strong non-GAAP income but with higher SG&A and R&D as it pushes multiple registrational programs toward 2027 Phase III readouts and seeks to build on CRENESSITY’s early success.
Neurocrine’s earnings call painted a picture of a company balancing near-term margin pressure against compelling growth and pipeline opportunities. With record revenue, a durable INGREZZA franchise, a promising CRENESSITY launch and a deep late-stage portfolio, management argued the long-term upside more than offsets current pricing, access and cost headwinds for investors.
